

Emilio Russo, Pharmacology Professor



Professional Biography

Emilio Russo first graduated in pharmaceutical chemistry and Technology at the University of Messina (Italy) and then in Medicine at the University of Catanzaro (Italy). He carried out a PhD in Pharmacology on in vitro and in vivo models of epilepsy at the School of Pharmacy, University of London. Postgraduate Research Assistant at the Pharmacology Department, School of Pharmacy of London, he then gained a lectureship at the University of Catanzaro in 2008 and then Associate Professor in Pharmacology at the School of Medicine of the same University in 2015. He has been the Director of the School of Specialization in Pharmacology between 2017 and 2020 and he has an active role in undergraduate and post-graduate teaching in Pharmacology.

Research interests

*Pharmacology and physiopathology of Epilepsies and Epileptogenesis.
Discovery of new potential anticonvulsant drugs.
Comorbidity of Epilepsy with psychiatric diseases.
Animal modes of Epilepsy.
Clinical efficacy and safety of Antiepileptic drugs.*

Research Activities

*Author of more than 200 publications on peer-reviewed Journals
Author of about 10 Chapters in books
Scopus ID: [57200140760](https://orcid.org/0000-0001-9000-5760)*

Boards and committees

*Coordinator of the antiseizure medications committee of the Italian League against Epilepsy (LICE) since 2017.
Component of the Italian Study group for cannabis of the Italian League against Epilepsy (LICE) since 2017.
Member of the Scientific Committee (CTS) of the Italian League against Epilepsy (LICE) since 2021.
PlosOne academic editor since 2016
Review Editor for *Frontiers in Neurology* – Sections Epilepsy and Paediatric Neurology since 2018
Review Editor for *Frontiers in Pharmacology* – Experimental Pharmacology and Drug Discovery section since 2015.*

Disclosures and Research Fundings

Emilio Russo has received speaker fees and participated at advisory boards for Eisai, UCB, Lundbeck and Arvelle Therapeutics and has received research fundings by Eisai, GW Pharmaceuticals, Kolffarma, Pfizer, Italian Ministry of Health (MoH), Italian Ministry of University and the Italian Medicine Agency (AIFA).
